We initiate Lancy at BUY with a target price of RMB22.92, based on 22.1x 2027E PE. We view Lancy as a scarce play capturing both beta and alpha value. 1) As medical aesthetics solutions become more affordable, leading downstream institutions are poised to strengthen their bargaining power. Having built a multi-brand, multi-tiered medical aesthetics network, Lancy is well positioned to deliver margin expansion and market share gains on the back of scaled procurement and group-level operational capabilities. 2) The women’s apparel sector is undergoing structural shifts towards premiumization and online sales, where designer brands are driving strong repeat purchases and building brand momentum through distinctive designs. Lancy is rejuvenating its brands and pivoting towards online channels, with the e-commerce methodology of LANCY FROM 25 set to be replicated across more business divisions. Furthermore, the company has launched its fourth Employee Stock Ownership Plan (ESOP), targeting an increase of RMB10.5bn in peak annual revenue during 2026–2028 compared with 2025 alongside an average NPM of 10% over the period, underscoring management’s confidence in long-term growth.
We project 2026/2027/2028 revenue of RMB6.56/7.21/7.85bn (+9.3/+9.9/+8.9% YoY) and attributable net profit of RMB353/458/554mn (-64.6/+29.6/+20.8% YoY; the YoY decline for 2026E reflecting a high base from non-recurring investment gains on the disposal of Ruoyuchen equity in 2025). In our SOTP model, we value the medical aesthetics/fashion women’s apparel/green infant & children’s wear and other segments at 26/16/14x 2027E PE — above their peers’ averages of 22.6/12.7/12.7x on iFinD consensus — to reflect Lancy’s scarcity as a leading medical aesthetics institution, its leading online transition in women’s apparel, its South Korea-focused infant & children’s wear business, and an A-share liquidity premium. This yields a combined target market cap of RMB10.14bn and our target price of RMB22.92. Initiate at BUY.
我有话说